Active — Not RecruitingPhase 3

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)

United States214 participantsStarted 2024-12-11

Plain-language summary

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Voyage

Who can participate

Age range18 Years – 74 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Diagnosis of GAD per DSM-5
✓. Male or female aged 18 to 74
✓. HAM-A Total Score ≥20

Exclusion criteria

✕. Certain psychiatric disorders (other than generalized anxiety disorder)
✕. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder
✕. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)
✕. Any clinically significant unstable illness

What they're measuring

Change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) total score at Week 12

Timeframe: Baseline to Week 12

Trial details

NCT IDNCT06741228

SponsorDefinium Therapeutics US, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-05

View on ClinicalTrials.gov More Generalized Anxiety Disorder trials